news – Page 171

First-in-Human Results of Terbium-161 PSMA Radioligand Therapy in mCRPC: Insights from the VIOLET Study

By MedXY 08/02/2025

A phase 1/2 trial demonstrates the safety of [161Tb]Tb-PSMA-I&T, a novel dual beta-Auger radioligand, in heavily pretreated metastatic castration-resistant prostate cancer patients, supporting further clinical investigation.

Clinical Updates Diabetes & Endocrinology news Specialties

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

By MedXY 08/02/2025

Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.

Clinical Updates news Psychiatry Specialties

Pramipexole Augmentation in Treatment-Resistant Unipolar Depression: A UK Multicentre Randomised Trial

By MedXY 08/02/2025

A UK multicentre, double-blind, placebo-controlled trial demonstrates that pramipexole augmentation at 2.5 mg reduces depressive symptoms in treatment-resistant unipolar depression at 12 weeks, with some adverse effects noted, supporting its clinical utility.

Clinical Updates news Radiology Rheumatology Specialties

Functional MRI Brain Activation as a Predictor of Response to TNF Inhibition in Rheumatoid Arthritis: Insights from the PreCePra Phase 3 Study

By MedXY 08/02/2025

A phase 3 trial indicates that fMRI-detected CNS pain activation may predict which rheumatoid arthritis patients respond best to TNF inhibitor therapy.

Clinical Updates news Oncology Specialties

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial

By MedXY 08/02/2025

Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.

Clinical Updates news Rheumatology Specialties

Sarilumab in Relapsing Polymyalgia Rheumatica: Clinical Efficacy and Patient-Reported Outcomes from Recent Phase 3 Trials

By MedXY 08/02/2025

Sarilumab demonstrates significant improvement in disease control and quality of life for patients with relapsing polymyalgia rheumatica, enabling glucocorticoid sparing and sustained remission.

Clinical Updates Diabetes & Endocrinology news Specialties

Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials

By MedXY 08/02/2025

Once-weekly insulin regimens (IcoSema, efsitora alfa) demonstrate non-inferior glycemic control compared to daily injections in type 2 diabetes, with advantages in hypoglycemia risk, weight, and injection burden.

Clinical Updates Diabetes & Endocrinology news Specialties

Automated Insulin Delivery in Young Children with Type 1 Diabetes: Insights from the LENNY Trial

By MedXY 08/02/2025

The LENNY trial demonstrates that the MiniMed 780G automated insulin delivery system improves glycaemic control and maintains safety in children aged 2–6 years with type 1 diabetes.

Clinical Updates Gastroenterology news Specialties

Pre-emptive TIPS vs Glue Obliteration for Acute Fundal Variceal Bleeding in Cirrhosis: Key Insights from the GAVAPROSEC Trial

By MedXY 08/02/2025

The GAVAPROSEC trial demonstrates that pre-emptive TIPS significantly reduces 1-year mortality and rebleeding in cirrhotic patients with acute fundal gastric variceal bleeding compared to glue obliteration plus NSBB.

Clinical Updates Gastroenterology news Specialties

EASE-CD: A Validated Endoscopic Ulcer Activity Score for Crohn’s Disease—Clinical Utility and Evidence from Randomized Trials

By MedXY 08/02/2025

The EASE-CD index offers a reliable, validated, and responsive tool for quantifying Crohn's disease ulcer activity in clinical trials and practice, improving upon prior endoscopic indices.

Clinical Updates Gastroenterology Internal Medicine news Specialties

Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results

By MedXY 08/02/2025

Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled trial.

Clinical Updates Gastroenterology news Specialties

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.

Cardiology Clinical Updates news Specialties

Evaluating the MISSION Act: Implications for Cardiovascular Procedure Outcomes in U.S. Veterans

By MedXY 08/02/2025

The MISSION Act reduced travel times to cardiac procedures for veterans distant from VA centers but was linked to higher short-term adverse cardiovascular events for PCI and CABG, highlighting complex trade-offs in access and care quality.

Cardiology Clinical Updates news Specialties

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

By MedXY 08/02/2025

The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.

Clinical Updates Hematology-Oncology news Specialties

Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials

By MedXY 08/02/2025

Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.

Clinical Updates news Public Health Specialties

Efficacy of the OurFutures Vaping eHealth Intervention in Preventing Adolescent E-Cigarette Use: Insights from a Landmark Australian Cluster RCT

By MedXY 08/02/2025

A large Australian cluster RCT demonstrates that a school-based eHealth intervention, OurFutures Vaping, significantly reduces adolescent e-cigarette use by 65% compared to usual health education over 12 months.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights$

Clinical Updates Hematology-Oncology news Specialties

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

By MedXY 08/02/2025

The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.

Cardiology Family Medicine & Nutrition news Specialties

Unlocking the Potential of the Soleus Muscle: A Key to Metabolic and Cardiovascular Health

By MedXY 08/02/2025

Learn about the critical role of the soleus muscle in metabolism, blood sugar regulation, and cardiovascular health, and discover effective exercises to enhance its function.

Clinical Updates Hematology-Oncology news Specialties

Fertility Outcomes in Advanced-Stage Classic Hodgkin Lymphoma: BrECADD Versus eBEACOPP in the HD21 Trial

By MedXY 08/02/2025

The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therapy for fertility preservation.

Clinical Updates Neurology news Specialties

Neuropsychiatric Symptoms and Their Impact on Daily Functioning in Cognitively Unimpaired Older Adults

By MedXY 08/02/2025

Neuropsychiatric symptoms such as decreased motivation and emotional dysregulation significantly impair daily functioning in older adults without cognitive impairment, highlighting the need for early identification and intervention.